End Of Fosamax Patent Heralds Payday For Generics
Patent protection for Merck & Co.'s Fosamax expired on Wednesday, giving other pharmaceutical companies the thumbs-up to start marketing generic versions of the popular osteoporosis drug....To view the full article, register now.
Already a subscriber? Click here to view full article